Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617905 | 0.87 | ALPL (0.48) | ALPLPTPN1WDR5IDH1MAOA | |
| SCHEMBL2653076 | 0.83 | ALPL (0.52) | ALPLPTPN1PPARGMCHR1ADRA2A | |
| SCHEMBL1542154 | 0.83 | ALPL (0.52) | ALPLPTPN1PPARGMCHR1ADRA2A | |
| SCHEMBL29843178 | 0.83 | ALPL (0.52) | ALPLPTPN1PPARGMCHR1ADRA2A | |
| Hydrochloric Acid SCHEMBL27749584 | 0.82 | ALPL (0.51) | ALPLPTPN1PPARGMCHR1ADRA2A | |
| SCHEMBL5704864 | 0.81 | TRPV4 (0.62) | ALPLTRPV4EPAS1 | |
| SCHEMBL3018907 | 0.80 | ALPL (0.58) | ALPLPTPN1PPARGMCHR1ADRA2A | |
| SCHEMBL16186184 | 0.80 | ALPL (0.49) | ALPLPTPN1PPARGMCHR1ADRA2A | |
| SCHEMBL2831975 | 0.80 | PTPN1 (0.51) | ALPLPTPN1MCHR1ADRA2ANPY5R | |
| SCHEMBL3017809 | 0.79 | GLA (0.58) | ALPLPTPN1PPARGMCHR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242861-A1 | Synthesis of amino-protected cyclohexane-1,4-diyldimethanamine and its derivatives | TAIGEN BIOTECHNOLOGY (TW) | 2008-10-02 | — | — | US | claimed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| EP-3890715-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-24 | — | — | US | disclosed |
| WO-2003028641-A2 | MCH RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
| EP-1296967-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | Tularik Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002041889-A2 | INDOLSULFONYL COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-1056743-A1 | BENZAMINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999031092-A1 | BENZAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242861-A1 | Synthesis of amino-protected cyclohexane-1,4-diyldimethanamine and its derivatives | DDC, PNMT, DDT | ALPL 4543/4885PTPN1 4768/4885PPARG 4272/4885 |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | ALPL 4445/4885PTPN1 2260/4885PPARG 3817/4885 |
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | OPRL1, OPRM1, OPRK1 | ALPL 4516/4885PTPN1 2577/4885PPARG 669/4885 |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | ALPL 3405/4885PTPN1 2628/4885PPARG 2323/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | ALPL 4445/4885PTPN1 2260/4885PPARG 3817/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | ALPL 4445/4885PTPN1 2260/4885PPARG 3817/4885 |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARA, PPARG, PPARD | ALPL 2463/4885PTPN1 1398/4885PPARG 2/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | ALPL 4503/4885PTPN1 1545/4885PPARG 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.